Humacyte, Inc. (HUMAW) is a Biotechnology company in the Healthcare sector, currently trading at $0.08. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: HUMAW trades at a trailing Price-to-Earnings (P/E) of -2.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.05.
Financials: revenue is $2M, -100%/yr average growth. Net income is $41M (loss), growing at -78.1%/yr. Net profit margin is -2003.6% (negative). Gross margin is -736.5% (-309 pp trend).
Balance sheet: total debt is $65M against $3M equity (Debt-to-Equity (D/E) ratio 20.86, leveraged). Current ratio is 3.69 (strong liquidity). Debt-to-assets is 55.7%. Total assets: $116M.
Analyst outlook: 1 / 1 analysts rate HUMAW as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 33/100 (Fail), Moat 0/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
